CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

At Science Day, Moderna outlined growth plans across infectious-disease vaccines, Intismeran, and rare-disease therapeutics. ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Moderna just received fantastic news.

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, ...

mCOMBRIAX is the world’s first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna’s fourth vaccine to receive a positive ...

The company's pending vaccine approvals could help the stock continue its rise.

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...